Healthcare
Definium Therapeutics, Inc.(DFTX)
Live Price
Offline$36.67
+49.80% today
1Y Change
+436.11%
Window
Jun 25, 2025 β Jun 22, 2026
- Market Cap
- $2.44B
- Revenue Growth
- 0.0%
- EPS Growth
- -33.8%
- Dividend Yield
- 0.0%
Coverage: 248 bars Β· Jun 25, 2025 β Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Definium Therapeutics, Inc. (DFTX) is a Healthcare stock with a market cap of $2.44B and listed on NASDAQ. The stock last traded around $36.67 and up 436.1% across the available one-year price window (Jun 25, 2025 β Jun 22, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -33.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -33.8%, free cash flow -66.3% with operating margin 0.0% and ROIC -44.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DFTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -33.8%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.4% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | β | -1.7% | +6.1% | +15.9% |
2026 Feb 26, 2026 | -5.4% | +0.9% | +1.5% | +9.5% |
2025 Nov 6, 2025 | -50.0% | +3.2% | +2.6% | +8.9% |
Benchmark Edge
DFTX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DFTX
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DFTX Max Drawdown
-24.79%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DFTX and SPY.
Company Overview
Definium Therapeutics, Inc.
NASDAQ Global Select
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The companyβs lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
- Leadership
- Robert Barrow
- IPO Date
- Nov 15, 2016
- Employees
- 74
- Street Address
- One World Trade Center
- Mailing
- New York, NY, 10007
- Region
- New York, NY, US
- Reporting Currency
- USD
- Investor Line
- 212 220 6633
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- β
- Price/Book
- 6.0
Growth
- Revenue
- 0.0%
- EPS
- -33.8%
- Free Cash Flow
- -66.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -84.4%
- ROIC
- -44.5%
Balance Sheet
- Debt/Equity
- β
- Current Ratio
- 6.29
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.